{"id":55728,"date":"2026-01-28T21:27:56","date_gmt":"2026-01-28T13:27:56","guid":{"rendered":"https:\/\/flcube.com\/?p=55728"},"modified":"2026-01-28T21:27:57","modified_gmt":"2026-01-28T13:27:57","slug":"roche-ct-388-obesity-drug-shows-22-5-weight-loss-in-phase-ii-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55728","title":{"rendered":"Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial"},"content":{"rendered":"\n

Roche<\/strong> (SWX: ROG<\/a>, OTCMKTS: RHHBY<\/a>) announced positive topline results from its Phase\u202fII clinical trial (CT388\u2011103)<\/strong> for CT\u2011388<\/strong>, an investigational GLP\u20111\/GIP receptor agonist<\/strong> in obesity. The once\u2011weekly subcutaneous injection achieved a placebo\u2011adjusted weight loss of 22.5% at 48 weeks<\/strong>, with weight reduction yet to reach a plateau and a clear dose\u2011response relationship observed.<\/p>\n\n\n\n

Clinical Trial Results & Key Findings<\/h2>\n\n\n\n
Metric<\/th>Result<\/th><\/tr><\/thead>
Trial<\/strong><\/td>CT388\u2011103 Phase\u202fII<\/td><\/tr>
Drug<\/strong><\/td>CT\u2011388 (GLP\u20111\/GIP receptor agonist)<\/td><\/tr>
Dosing<\/strong><\/td>Once\u2011weekly SC, titrated to maximum 24\u202fmg<\/td><\/tr>
Primary Endpoint<\/strong><\/td>Placebo\u2011adjusted weight loss<\/td><\/tr>
Weight Loss at 48 Weeks<\/strong><\/td>22.5%<\/strong> (Efficacy Estimand)<\/td><\/tr>
Dose Response<\/strong><\/td>Clear relationship observed<\/td><\/tr>
Status<\/strong><\/td>Weight loss not yet plateaued<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n